Capital International, Inc. Alnylam Pharmaceuticals, Inc. Transaction History

Capital International, Inc.

$7.11 Billion
Q1 2024

A detailed history of Capital International, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital International, Inc. holds 93,376 shares of ALNY stock, worth $23.8 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares

93,376

Previous 100,022 6.64%

Holding current value

$23.8 Million

Previous $19.1 Million 27.11%

% of portfolio

0.2%

Previous 0.31%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$146.51 - $198.2 $973,705 - $1.32 Million	-6,646 Reduced 6.64%	93,376 $14 Million
Q4 2023 Feb 13, 2024	BUY	$151.41 - $196.57 $537,354 - $697,626	3,549 Added 3.68%	100,022 $19.1 Million
Q3 2023 Nov 13, 2023	BUY	$170.77 - $211.65 $6.6 Million - $8.18 Million	38,626 Added 66.77%	96,473 $17.1 Million
Q2 2023 Aug 11, 2023	BUY	$185.01 - $212.05 $1.21 Million - $1.39 Million	6,555 Added 12.78%	57,847 $11 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $745,618 - $961,433	4,082 Added 8.65%	51,292 $10.3 Million

Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $1.51 Million - $1.97 Million	8,148 Added 20.86%	47,210 $11.2 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $429,612 - $719,432	-3,101 Reduced 7.35%	39,062 $7.82 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $2.74 Million - $3.86 Million	22,773 Added 117.45%	42,163 $6.15 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $2.47 Million - $3.37 Million	19,390 New	19,390 $3.17 Million

Others Institutions Holding ALNY

# of Institutions

585

Shares Held

104M

Call Options Held

2.82M

Put Options Held

1.75M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.4B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.

Account

Capital International, Inc. Alnylam Pharmaceuticals, Inc. Transaction History